Tinley Beverage Enters White Label Agreement With Bevcanna For Canadian Market

It looks like Tinley Beverage Co (CSE: TNY) might finally see its products hit Canadian shelves. The firm this morning announced that it has signed with BevCanna Enterprises (CSE: BEV) for the white label production of its Tinley’s Tonics cannabis beverages.

Under the arrangement, the company will see its Tinley’s Tonics products sold under the Tinley’s Classics banners, a result of slight changes to formulations to better suite Canadian regulations and consumer tastes. Products to be produced under the arrangement include Stone Daisy, Moscow Mule, Mystic Dove and Juniper Sky, all of which are based on beverage alcohol flavour profiles.

The white label arrangement will see Tinley commit to annual minimum order quantities, with commercial production of the beverages to be underway shortly, and simultaneous to the 60-day NNCP required following certain formulation changes. Once produced, the products are to be marketed via Great North Distribution, whom has reach across every province in the country.

In addition to Tinley’s Tonics, the company provided an update on its Tinley ’27 Collection, which is being produced by Peak Processing Solutions in Ontario. The products were reportedly delayed as a result of changes in Health Canada’s packaging requirements, with the company now waiting on the 60-day NNCP approval following changes. Commercial production is to begin following successful confirmatory testing, simultaneous to this 60 day time delay.

Lastly, the company has reportedly seen strong demand from dispensaries within Canada for its products, with Great North Distributors indicating that several provincial cannabis board have provided “strong indicative interest” in carrying the products.

Tinley Beverage Co last traded at $0.25 on the CSE.

FULL DISCLOSURE: Tinley Beverage is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Tinley Beverage on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.